Report on the Annual Global Survey 2016
Compiled annually, the Annual Global Survey (AGS) provides demographic and other data on people with hemophilia, von Willebrand disease, other rare factor deficiencies, and inherited platelet disorders throughout the world.
Molecular Diagnosis of von Willebrand Disease
The accurate diagnosis of von Willebrand disease (VWD) is crucial to its management. This resource describes the techniques used to determine the genetic nature, or genotype, of a suspected case of VWD. The companion monograph, TOH 55 Diagnosis of von Willebrand Disease: Phenotypic Characterization, provides a detailed review of the laboratory tests that can be […]
Introduction to Bleeding Disorders
Adapted from: Global NMO Training 2016 plenary presentation by Glenn PierceReviewed by: Glenn PierceEdited by: Georghia Michael This first eLearning module of the Treatment Products program explains how blood clots, how clotting factors work together in the coagulation cascade, what goes wrong in the case of factor deficiency, and how factor replacement therapy works by […]
Annual Global Survey Mini Report 1: Gender
The WFH Annual Global Survey (AGS) mini reports are advocacy tools that provide more in-depth perspective and context to AGS data. Lack of diagnosis and treatment for women and girls with bleeding disorders remains a challenge in our community. Highlighting gender data from the AGS can help bring awareness to the issues facing women and […]
Proceedings of the WFH’s Tenth Global Forum on Research and Treatment Products for Bleeding Disorders
A summary of discussions held at the Tenth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which brings together patient groups, healthcare providers, researchers, regulators, industry representatives, and not-for-profit fractionators.
In-HemoAction Card Game
Using the universal language of pictures, children around the world can learn about hemophilia in a fun, easy to understand, and interactive way. The In-HemoAction cards teach children how to prevent bleeds and manage hemophilia. An update of the hugely popular HemoAction game, this edition features additional content covering prophylaxis, inhibitors, bypassing agents, immune tolerance […]
Factor Replacement Therapy Schematic
This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking, and how infusion of replacement therapy works to achieve normal levels of blood clotting. It also illustrates the clotting factor cascade and highlights the points in the cascade where each type of hemophilia treatment product […]
Pediatric Haemophilia Activities List (PedHAL) – Parents’ Version
Certified translations for the PedHAL are available in the following languages: Dutch, Flemish, French (Canadian and European), English (UK and USA/Canadian), Danish, Norwegian, Spanish, Portugese, Czech, Bulgarian, Chinese, Japanese, Arabic, Turkish, Swedish, Polish, Korean, Serbian, South African, and Italian. The PedHAL is available free of charge to clinicians and individuals and for a fee to […]
Pediatric Haemophilia Activities List (PedHAL) – Childrens’/Teenagers’ Version
Certified translations for the PedHAL are available in the following languages: Dutch, Flemish, French (Canadian and European), English (UK and USA/Canadian), Danish, Norwegian, Spanish, Portugese, Czech, Bulgarian, Chinese, Japanese, Arabic, Turkish, Swedish, Polish, Korean, Serbian, South African, and Italian. The PedHAL is available free of charge to clinicians and individuals and for a fee to […]
Congenital Fibrinogen Disorders: Clinical features and management
In the Wednesday morning session on rare and ultra-rare bleeding disorders, Philippe de Moerloose disscusses the issues of congenital fibrinogen disorders.
Factor FXIII Deficiency
In the Wednesday morning session on rare and ultra-rare bleeding disorders, Diane Nugent presents work on FXIII deficiency.
Health Technology Assessment: Introduction, American perspective, and European perspective
In the Tuesday afternon session on Health Technology Assessments (HTA), Mark Skinner introduces the topic and then Cliff Goodman and Chris Henshall alternate to present the American and European perspectives, respectively.